English

This report was produced by a Federal TB task force that was reconvened by CDC in November 2006. The task force drafted an updated action plan to address the issue of multidrug-resistant TB (MDR TB) and extensively drug-resistant TB (XDR TB). Task force members were charged with articulating the most pressing problems, identifying barriers to improvement, and recommending specific action steps to improve prevention and control of XDR TB in their respective areas.

This report provides data on the mortality among patients with TB and associations with HIV infection. To investigate the impact of HIV on risk for death during TB treatment in the United States, data were analyzed for all culture-positive patients with TB from 1993 to 2008. The proportion that died was determined and stratified by HIV test result. Mortality data were restricted to patients reported before 2007.

Dr. Mark Gilbert of the BC Centre for Disease Control talks about tuberculosis in a minute-long video.

An infographic with information on latent TB, TB disease, TB in British Columbia, TB globally, and TB symptoms,

Dr. Mark Gilbert of the BC Centre for Disease Control talks about the prevalence of tuberculosis in British Columbia.

A fact sheet on the TB skin test, including information on latent TB infection, TB disease, and what a positive/negative skin test means. The fact sheet also has information on testing after receiving the BCG vaccine.

This serial presents updated guidelines to US public health officials, healthcare providers, and laboratory workers for use of FDA-approved interferon gamma release assays (IGRAs) to diagnose both active and latent TB infection in adults and children. These guidelines include use of the QuantiFERON-TB Gold In-Tube Test (QFT-GIT) and the T-SPOT.TB Test (T-Spot), two new IGRAs that were not included in the previous guidelines published in 2005. The antigens, methods, and interpretation criteria for these assays differ from those for IGRAs approved previously.